Anthracycline‑Induced Cardiac Toxicity: A Clinical Review

Abstract

Anthracyclines (ATCs) have a great efficacy against many types of cancer and is currently considered a cornerstone in the treatment of numerous pediatric and adult hematological and solid tumors. Great advances have been achieved after the entry of ATC group into the cancer treatment in the early 1960s, and the overall survival ratio has increased from 30% to near 70%. Due to their significant role and great value in cancer therapy, which is persistent to date, ATCs are listed in the World Health Organization model list of essential medicines. The clinical use of ATC such as doxorubicin and daunorubicin can be viewed as a sort of double-edged sword. On the one hand, ATCs play an undisputed key role in the treatment of many neoplastic diseases; on the other hand, the administration of ATC is associated with the risk of severe adverse effects. The most common side effect of the ATC group is cardiotoxicity (CTX), which may limit its use and increases mortality and morbidity rates. The clinical use of ATC is limited by unique maximum total cumulative dose (approximately 350 mg/m²) limiting CTX. ATC CTX is cumulative dose-dependent and is in most of the occasions irreversible. Lowering the cumulative dose has been proved to be useful in minimize the risk of heart failure (HF), but, yet, there is a growing concern that HF might occur following doses that were thought to be safe. The average incidence of HF is around 5% at a cumulative dose of 400 mg/m² that becomes higher above 500 mg/m², albeit with substantial individual variation. The newer generations ATC medications such as epirubicin, idarubicin, and mitoxantrone were thought to be safer; however, subsequent clinical studies showed more or less similar toxicity profiles. The use of cardioprotective agents (e.g., dexrazoxane and amifostine) has been associated with improved safety range; however, questions are looming on their effect on ATC antitumor effects. An overwhelming amount of clinical evidence suggests that ATCs are too good to be old. Yet, they would look much better if they caused less harm to the heart when administered as either single agents or in combination with otherwise promising new drugs. In this review article, we present a comprehensive account on the ATC and provide up to date data on their clinical use and toxicity profile. In addition, we provide a contemporary approach on the early detection, diagnosis, and treatment of ATC CTX.

Keywords

Anthracyclines - cardiac failure - daunorubicin - dexrazoxane - doxorubicin

Publication History

Received: 29 April 2019

Accepted: 04 August 2019

Article published online:
03 June 2021

• References

• 1 Gatta G, Capocaccia R, Coleman MP, Ries LA, Berrino F. Childhood cancer survival in Europe and the United States. Cancer 2002; 95: 1767-72
• 2 20th edition of the WHO model list of essential drugs, August 2017. Available from: https://www.who.int/medicines/publications/essentialmedicines/en/. [Last accessed on 2019 Aug 12]
• 3 Von Hoff DD, Layard MW, Basa P, Davis Jr. HL, Von Hoff AL, Rozencweig M. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7
• 4 Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229
• 5 Erdoğan D, Yücel H, Alanoğlu EG, Uysal BA, Koçer M, Ozaydın M. et al. Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy?. Turk Kardiyol Dern Ars 2011; 39: 646-53
• 6 Minotti G, Sarvazyan N. The anthracyclines: When good things go bad. Cardiovasc Toxicol 2007; 7: 53-5
• 7 Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. et al. Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 2008; 26: 3777-84
• 8 Salvatorelli E, Menna P, Chello M, Covino E, Minotti G. Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin. J Pharmacol Exp Ther 2017; 362: 263-70
• 9 Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D. et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 2016; 66: 309-25
• 10 Tajiri K, Aonuma K, Sekine I. Cardio-oncology: A multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol 2017; 47: 678-82
• 11 Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS. et al. Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol 2016; 32: 831-41
• 12 Weiss RB. The anthracyclines: Will we ever find a better doxorubicin?. Semin Oncol 1992; 19: 670-86
• 13 Borchmann P, Hübel K, Schnell R, Engert A. Idarubicin: A brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997; 35: 80-3
• 14 Toffoli G, Sorio R, Aita P, Crivellari D, Corona G, Rimondi G. et al. Pharmacology of chronic oral daily administration of idarubicin. Haematologica 1997; 82: 1-3
• 15 Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM. et al. Idarubicin cardiotoxicity: A retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13: 2827-34
• 16 Lothstein L, Israel M, Sweatman TW. Anthracycline drug targeting: Cytoplasmic versus nuclear – A fork in the road. Drug Resist Updat 2001; 4: 169-77
• 17 Dabich L, Bull FE, Beltran G, Athens JW, Coltman Jr. CA, Weick JK. et al. Phase II evaluation of aclarubicin in refractory adult acute leukemia: A Southwest Oncology Group Study. Cancer Treat Rep 1986; 70: 967-9
• 18 Estorch M, Carrió I, Martínez-Duncker D, Berná L, Torres G, Alonso C. et al. Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. J Clin Oncol 1993; 11: 1264-8
• 19 Thomas X, Le QH, Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Ann Hematol 2002; 81: 504-7
• 20 Gabizon AA, Patil Y, La-Beck NM. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Updat 2016; 29: 90-106
• 21 Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-41
• 22 Menna P, Salvatorelli E, Minotti G. Anthracycline degradation in cardiomyocytes: A journey to oxidative survival. Chem Res Toxicol 2010; 23: 6-10
• 23 Mele D, Tocchetti CG, Pagliaro P, Madonna R, Novo G, Pepe A. et al. Pathophysiology of anthracycline cardiotoxicity. J Cardiovasc Med (Hagerstown) 2016; 17 (01) e3-11
• 24 Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS. et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 2013; 119: 3555-62
• 25 Bagnes C, Panchuk PN, Recondo G. Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf 2010; 5: 93-6
• 26 Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from “diastolic heart failure” or from misdiagnosis? A prospective descriptive study. BMJ 2000; 321: 215-8
• 27 Kupeli S. Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors. World J Cardiol 2014; 6: 555-61
• 28 Mulrooney DA, Nunnery SE, Armstrong GT, Ness KK, Srivastava D, Donovan FD. et al. Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphoma. Cancer 2014; 120: 3536-44
• 29 Figueroa MS, Peters JI. Congestive heart failure: Diagnosis, pathophysiology, therapy, and implications for respiratory care. Respir Care 2006; 51: 403-12
• 30 McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005; 365: 1877-89
• 31 Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F. et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131: 1981-8
• 32 Moussa E, Zamzam M, Kamel A, Salah Z, Attia I, Gaber L. et al. Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma. J Egypt Natl Canc Inst 2017; 29: 53-6
• 33 Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25: 72-85
• 34 Mele D, Nardozza M, Spallarossa P, Frassoldati A, Tocchetti CG, Cadeddu C. et al. Current views on anthracycline cardiotoxicity. Heart Fail Rev 2016; 21: 621-34
• 35 Rathe M, Carlsen NL, Oxhøj H. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48: 663-7
• 36 D’Amore C, Gargiulo P, Paolillo S, Pellegrino AM, Formisano T, Mariniello A. et al. Nuclear imaging in detection and monitoring of cardiotoxicity. World J Radiol 2014; 6: 486-92
• 37 Medical Advisory Secretariat. Magnetic resonance imaging (MRI) for the assessment of myocardial viability: An evidence-based analysis. Ont Health Technol Assess Ser 2010; 10: 1-45
• 38 de Geus-Oei LF, Mavinkurve-Groothuis AM, Bellersen L, Gotthardt M, Oyen WJ, Kapusta L. et al. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med 2011; 52: 560-71
• 39 Özdoğru I. Anthracycline-induced cardiotoxicity. Arch Turk Soc Cardiol 2014; 42: 274-6
• 40 Iarussi D, Indolfi P, Galderisi M, Bossone E. Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 2000; 25: 676-88
• 41 Sieswerda E, van Dalen EC, Postma A, Cheuk DK, Caron HN, Kremer LC. et al. Medical interventions for treating anthracyclineinduced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev 2011;(9):CD008011. doi: 10.1002/14651858.CD008011.pub2
• 42 Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M. et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study. Int J Cardiol 2013; 167: 2306-10
• 43 Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT (1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009; 60: 373-81
• 44 Bilginoğlu A, Aydın D, Ozsoy S, Aygün H. Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Turk Kardiyol Dern Ars 2014; 42: 265-73
• 45 Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O. et al. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11: 1029-33
• 46 Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL. et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11: 950-61
• 47 Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ. et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-hodgkin lymphoma: A Report of the children’s oncology group randomized trial pediatric oncology group 9404. J Clin Oncol 2016; 34: 854-62
• 48 Tien CC, Peng YC, Yang FL, Subeq YM, Lee RP. Slow infusion rate of doxorubicin induces higher pro-inflammatory cytokine production. Regul Toxicol Pharmacol 2016; 81: 69-76
• 49 van Dalen EC, van der Pal HJ, Kremer LC. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2016; 3: CD005008
• 50 Levitt GA, Dorup I, Sorensen K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br J Haematol 2004; 124: 463-8